Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
HANGZHOU, China and SHAOXING, China, Jan. 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors. ASC61 is an oral potent and highly selective PD-L1 small molecule inhibitor and blocks PD-1/PD-L1...
GSK Singapore announces availability of Shingrix in Singapore for shingles prevention
SINGAPORE, Jan. 10, 2022 /PRNewswire/ -- GlaxoSmithKline (GSK) Singapore announced that a new vaccine to help protect against shingles, Shingrix, is now available in Singapore. Shingrix is a non-live, recombinant subunit adjuvanted vaccine, given intramuscularly in two doses, for the prevention of shingles (herpes zoster). The vaccine was initially approved for adults aged 50 years and over, with the indication expanded...
CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China
TIANJIN, China, Jan. 9, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China ("NMPA") granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) ("MCV4", trade name: Menhycia™), making it the first of its kind to be authorized in China. Leveraging CanSinoBIO's industry-leading synthetic biotechnology and formulation technology...
SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE
SINGAPORE, Jan. 7, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has appointed Dr. Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis' technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include developing and implementing the Group's global Vascular Interventions R&D strategy, driving the enhancement of R&D and product capabilities, and...
Healthcare providers can expect to receive US$725 reimbursement from CMS when using NGS-based Sentosa(R) SQ HIV-1 Genotyping Assay
FAIRFIELD, N.J., Jan. 7, 2022 /PRNewswire/ -- Vela Diagnostics announced that its Sentosa® SQ HIV-1 Genotyping Assay is covered for reimbursement from The Centers for Medicare and Medicaid (CMS) starting January 2022. Based on the 2022 Clinical Diagnostic Laboratory Fee Schedule by CMS, healthcare providers using the Sentosa® SQ HIV-1 Genotyping Assay solution with the assigned descriptor for therapeutic...
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022. The company has been invited to participate via a...
100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
TAIPEI, Jan. 7, 2022 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure in hospitalized mild, moderate including ICU severe patients. In line with the plan, GoldenBiotech will submit the final clinical trial...
Li Jian Quan, Chairman of WINNER MEDICAL Co., Ltd., Was Invited to “DIALOGUE PROGRAM” in CCTV-2 (China Central Television)
SHENZHEN, China, Jan. 7, 2022 /PRNewswire/ -- On the evening of January 1, Li Jian quan, chairman of Winner Medical, was a guest on "DIALOGUE PROGRAM" in CCTV-2 (China Central Television) as a representative of entrepreneurs. In the interview, he said that only by insisting on innovation can we better serve the healthy life of the whole people....
Elekta to appoint Tobias Hägglöv as Chief Financial Officer
STOCKHOLM, Jan. 7, 2022 /PRNewswire/ -- Elekta (STO: EKTA-B) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. Tobias Hägglöv has previously held the role of CFO at Recipharm as well as senior management positions at LEAX, Electrolux, SAS and Accenture. Gustaf Salford, CEO of Elekta, said: "I'm...
Infinitus Wins Best Companies to Work for in Asia Award
GUANGZHOU, China, Jan. 7, 2022 /PRNewswire/ -- On December 30, human resources magazine HR Asia announced its list of the Best Companies to Work for in Asia 2021. Infinitus (China) Company Ltd., along with 42 companies including KPMG, Kimberly-Clark and Coach, were selected from 278 candidates to receive the coveted honor. The...
